In a preclinical study, dual blockade of TIGIT and PD-1 can specifically enhance the anti-tumor effect of CD8+ T cells with synergistic inhibition efficacy, with the majority of the treated animals achieving a complete response (CR)12. This evidence concerns the gene CD8A and neoplasm.